UBS Group
CPIX icon

UBS Group’s Cumberland Pharmaceuticals CPIX Stock Holding History

UBS Group’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9K Sell
5,189
-10,197
-66% -$39.3K ﹤0.01% 8048
2025
Q4 		$61.2K Buy
15,386
+14,559
+1,760% +$43.1K ﹤0.01% 7126
2025
Q3 		$2.58K Sell
827
-7,991
-91% -$26.6K ﹤0.01% 9150
2025
Q2 		$29.5K Buy
8,818
+3,481
+65% +$16.5K ﹤0.01% 8169
2025
Q1 		$22.6K Sell
5,337
-2,858
-35% -$11.9K ﹤0.01% 8144
2024
Q4 		$19.4K Sell
8,195
-1,476
-15% -$2.17K ﹤0.01% 7891
2024
Q3 		$12.4K Buy
9,671
+2,801
+41% +$3.88K ﹤0.01% 7638
2024
Q2 		$10.5K Buy
6,870
+5,077
+283% +$7.98K ﹤0.01% 7686
2024
Q1 		$3.01K Buy
1,793
+1,683
+1,530% +$3.36K ﹤0.01% 7787
2023
Q4 		$197 Buy
+110
New +$202 ﹤0.01% 8819
2023
Q3 		– Sell
-8,616
Closed -$12.7K – 9529
2023
Q2 		$12.7K Buy
8,616
+5,792
+205% +$9.99K ﹤0.01% 7067
2023
Q1 		$5.51K Sell
2,824
-899
-24% -$2.14K ﹤0.01% 8033
2022
Q4 		$8.38K Buy
+3,723
New +$8.64K ﹤0.01% 8781
2022
Q3 		– Sell
-3,783
Closed -$8K – 10413
2022
Q2 		$8K Buy
3,783
+503
+15% +$1.16K ﹤0.01% 8292
2022
Q1 		$9K Buy
+3,280
New +$10.9K ﹤0.01% 8537
2021
Q4 		– Sell
-1,933
Closed -$5K – 10308
2021
Q3 		$5K Buy
1,933
+1,468
+316% +$4.36K ﹤0.01% 8524
2021
Q2 		$1K Sell
465
-2,514
-84% -$7.4K ﹤0.01% 9135
2021
Q1 		$9K Buy
2,979
+881
+42% +$2.86K ﹤0.01% 7995
2020
Q4 		$6K Sell
2,098
-103
-5% -$312 ﹤0.01% 7750
2020
Q3 		$7K Sell
2,201
-1,932
-47% -$6.35K ﹤0.01% 7103
2020
Q2 		$14K Buy
4,133
+1,271
+44% +$4.62K ﹤0.01% 6780
2020
Q1 		$10K Buy
2,862
+1,316
+85% +$5.89K ﹤0.01% 6919
2019
Q4 		$8K Buy
+1,546
New +$8.16K ﹤0.01% 7383
2019
Q2 		– Sell
-1,000
Closed -$6K – 7893
2019
Q1 		$6K Sell
1,000
-2,711
-73% -$15.7K ﹤0.01% 7073
2018
Q4 		$22K Sell
3,711
-1,215
-25% -$7.27K ﹤0.01% 6697
2018
Q3 		$28K Buy
4,926
+2,104
+75% +$12.4K ﹤0.01% 6578
2018
Q2 		$17K Buy
2,822
+1,393
+97% +$8.71K ﹤0.01% 6804
2018
Q1 		$10K Sell
1,429
-781
-35% -$5.38K ﹤0.01% 6854
2017
Q4 		$16K Buy
2,210
+139
+7% +$1.02K ﹤0.01% 6718
2017
Q3 		$15K Sell
2,071
-1,059
-34% -$7.32K ﹤0.01% 6641
2017
Q2 		$22K Buy
3,130
+1,728
+123% +$11.4K ﹤0.01% 6220
2017
Q1 		$10K Sell
1,402
-94
-6% -$570 ﹤0.01% 6600
2016
Q4 		$8K Sell
1,496
-465
-24% -$2.42K ﹤0.01% 7026
2016
Q3 		$10K Buy
1,961
+1,065
+119% +$5.01K ﹤0.01% 6775
2016
Q2 		$4K Buy
896
+118
+15% +$541 ﹤0.01% 7214
2016
Q1 		$3K Buy
778
+228
+41% +$1.09K ﹤0.01% 7183
2015
Q4 		$3K Sell
550
-1,310
-70% -$7.46K ﹤0.01% 7866
2015
Q3 		$11K Buy
+1,860
New +$11.6K ﹤0.01% 7197
2015
Q1 		– Sell
-984
Closed -$6K – 8890
2014
Q4 		$6K Buy
+984
New +$5.05K ﹤0.01% 8812

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS Group's CPIX Position: Q1 2026 in Review

UBS Group reduced its Cumberland Pharmaceuticals (CPIX) stake by 66% in Q1 2026, selling an estimated $39.3K and leaving 5,189 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8048.

UBS Group first reported a position in CPIX in Q4 2014 and has held it in 39 quarters since. The position peaked at $61.2K in Q4 2025. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2026.

  • UBS Group held 5,189 shares of Cumberland Pharmaceuticals worth $16.9K as of Q1 2026.
  • UBS Group sold 10,197 Cumberland Pharmaceuticals shares in Q1 2026, an estimated $39.3K.
  • Cumberland Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8048 holding.
  • UBS Group first reported a position in Cumberland Pharmaceuticals in Q4 2014 and has held it in 39 quarters since.
  • UBS Group's Cumberland Pharmaceuticals position peaked at $61.2K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.